Multiple Myeloma Gene-Edited Cell Lines for Drug Discovery

Multiple myeloma (MM) accounts for approximately 1.8% of all new cancer cases and 2.1% of all cancer deaths in the United States, with an estimated 35,780 new cases and 12,540 deaths in 2024 (NCI SEER). Globally, the World Health Organization (WHO) reported 176,404 new cases and 117,077 deaths in 2022, with incidence rates highest in Australia/New Zealand and Northern Europe. Key risk factors include age (median diagnosis at 69), male sex, African ancestry, obesity, and monoclonal gammopathy of undetermined significance (MGUS). The 5-year relative survival rate for MM has improved to 59.8% (2014-2020) due to novel therapies, but remains low for high-risk cytogenetic subtypes (e.g., del(17p), t(4;14)) with median survival under 3 years (NCI).

Multiple myeloma is an ideal model for mechanistic studies due to its well-characterized clonal heterogeneity, defined cytogenetic subtypes, and the availability of large public datasets (e.g., CoMMpass, TCGA). Open questions include the role of the bone marrow microenvironment in drug resistance, the evolution of subclones under therapy pressure, and the identification of synthetic lethal vulnerabilities in high-risk genetic backgrounds. Gene-edited cell models enable precise dissection of these mechanisms.

The pathogenesis of multiple myeloma involves several key pathways:

• • NF-κB pathway: Constitutive activation via mutations in TRAF3, CYLD, or BIRC2/BIRC3 leads to increased survival and proliferation.
• • MAPK/ERK pathway: Activating mutations in KRAS (25%), NRAS (20%), or BRAF (4%) drive uncontrolled growth.
• • PI3K/AKT/mTOR pathway: PTEN loss or PIK3CA mutations (rare) activate this survival pathway.
• • JAK/STAT pathway: IL-6 signaling through JAK/STAT3 promotes myeloma cell growth and drug resistance.

Data from TCGA (Nature 2014) and COSMIC v99.

Key deregulated signaling networks in multiple myeloma include:

• • Wnt/β-catenin: Overexpression of Wnt ligands (e.g., Wnt3a) and reduced DKK1 lead to β-catenin stabilization and proliferation.
• • Notch: Notch1 and Notch2 activation promotes cell adhesion and drug resistance.
• • B cell receptor (BCR) signaling: Mutations in BTK, PLCγ2, and CARD11 are rare but can activate NF-κB.
• • DNA damage repair: TP53 mutations and ATM/ATR alterations impair DNA repair, leading to genomic instability.

Organoid models derived from patient bone marrow aspirates better recapitulate the tumor microenvironment and clonal heterogeneity, but are technically challenging and less scalable than cell lines.

• • Patient-derived xenografts (PDX): Engraftment of primary MM cells into immunodeficient mice (e.g., NSG) preserves tumor heterogeneity and stroma interactions.
• • Genetically engineered mouse models (GEMM): Vk*MYC model (spontaneous MM with MYC activation) and Eμ-XBP-1 model (XBP-1 overexpression) recapitulate disease features.
• • Induced models: ST33MM (syngeneic) and 5TGM1 (C57BL/6) are used for immune-competent studies.

CRISPR/Cas9 gene editing enables the generation of isogenic cell lines with precise genetic modifications. For example, TP53 knockout in MM.1S cells (TP53-/-) models loss-of-function in a wild-type background, while KRAS G12D knock-in in RPMI-8226 cells allows study of oncogenic activation. Commercially available, sequence-verified gene-edited cell models accelerate research by eliminating the need for in-house editing and validation. These models are used for target validation, drug screening, and resistance mechanism studies.

Knockout and knock-in cell lines are used to validate candidate driver genes identified from sequencing studies. For example, TP53 knockout in MM.1S cells confirmed its role in genomic instability and sensitivity to DNA-damaging agents. NRAS Q61R knock-in in RPMI-8226 cells demonstrated increased MAPK signaling and sensitivity to MEK inhibitors.

Isogenic pairs (e.g., wild-type vs. KRAS G12D) enable high-throughput screening to identify compounds with selective activity against mutant cells. Resistance modeling involves chronic drug exposure in gene-edited lines to identify acquired mutations (e.g., BTK C481S in ibrutinib resistance).

CRISPR synthetic lethality screens in isogenic lines (e.g., TP53-/-) identify genes whose loss is selectively lethal in the mutant background. For example, PRMT5 was identified as a synthetic lethal target in TP53-mutant multiple myeloma, leading to clinical trials of PRMT5 inhibitors.